Early interaction of adeno-associated virus serotype 8 vector with the host immune system following intramuscular delivery results in weak but detectable lymphocyte and dendritic cell transduction

Human Gene Therapy

Volumn 26, Issue 1, 2015, Pages 1-13

  Gernoux, Gwladys ^a,b   Guilbaud, Mickaël ^a,b   Dubreil, Laurence ^b,c,d   Larcher, Thibaut ^b,c,d   Babarit, Candice ^b,c,d   Ledevin, Mireille ^b,c,d   Jaulin, Nicolas ^a,b   Planel, Pierre ^a   Moullier, Philippe ^a,b,e   Adjali, Oumeya ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c INRA UMR 703   (France)

^d LUNAM UNIVERSITÉ   (France)

^e UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR; VIRUS RNA;

ADENO ASSOCIATED VIRUS 8; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; GENE EXPRESSION; GENETIC TRANSDUCTION; IMMUNE SYSTEM; LYMPH NODE; MALE; NONHUMAN; SPLEEN; T LYMPHOCYTE; TIBIALIS ANTERIOR MUSCLE; TRANSGENE; VIRUS GENOME; ADMINISTRATION AND DOSAGE; ANIMAL; CELL LINE; CLASSIFICATION; DEPENDOPARVOVIRUS; GENE DOSAGE; GENE TRANSFER; GENE VECTOR; GENETIC TRANSCRIPTION; GENETICS; HUMAN; IMMUNOLOGY; LIVER; LYMPHOCYTE; METABOLISM; MOUSE; SEROTYPE; TISSUE DISTRIBUTION;

ADENO-ASSOCIATED VIRUS;

ANIMALS; ANTIGEN-PRESENTING CELLS; CELL LINE; DENDRITIC CELLS; DEPENDOVIRUS; GENE DOSAGE; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GENOME, VIRAL; HUMANS; LIVER; LYMPHOCYTES; MALE; MICE; RNA, VIRAL; SEROGROUP; TISSUE DISTRIBUTION; TRANSCRIPTION, GENETIC; TRANSDUCTION, GENETIC; TRANSGENES;

EID: 84921520591     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2014.070     Document Type: Article

References (63)

1. Rivera VM, Gao GP, Grant RL, et al. Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood 2005; 105:1424-1430.
2. Stieger K, Le Meur G, Lasne F, et al. Long-term doxycyclineregulated transgene expression in the retina of nonhuman primates following subretinal injection of recombinant AAV vectors. Mol Ther 2006;13:967-975.
3. Warrington KH Jr., and Herzog RW. Treatment of human disease by adeno-associated viral gene transfer. Hum Genet 2006;119:571-603.
4. Niemeyer GP, Herzog RW, Mount J, et al. Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood 2009;113:797-806.
5. Herzog RW, Mount JD, Arruda VR, et al. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. Mol Ther 2001;4:192-200.
6. Favre D, Blouin V, Provost N, et al. Lack of an immune response against the tetracycline-dependent transactivator correlates with long-term doxycycline-regulated transgene expression in nonhuman primates after intramuscular injection of recombinant adeno-associated virus. J Virol 2002;76:11605-11611.
7. Chenuaud P, Larcher T, Rabinowitz JE, et al. Autoimmune anemia in macaques following erythropoietin gene therapy. Blood 2004;103:3303-3304.
8. Gao G, Lebherz C, Weiner DJ, et al. Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood 2004;103:3300-3302.
9. Ross CJ, Twisk J, Bakker AC, et al. Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447 × beneficial mutation. Hum Gene Ther 2006;17:487-499.
10. Mingozzi F, Maus MV, Hui DJ, et al. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med 2007;13:419-422.
11. Mingozzi F, Meulenberg JJ, Hui DJ, et al. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood 2009;114:2077-2086.
12. Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011;365:2357-2365.
13. Martino AT, Suzuki M, Markusic DM, et al. The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. Blood 2011;117:6459-6468.
14. Rogers GL, Martino AT, Zolotukhin I, et al. Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B. J Transl Med 2014;12:25.
15. Mingozzi F, Liu YL, Dobrzynski E, et al. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest 2003;111:1347-1356.
16. Mingozzi F, Hasbrouck NC, Basner-Tschakarjan E, et al. Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood 2007;110:2334-2341.
17. Toromanoff A, Adjali O, Larcher T, et al. Lack of immunotoxicity after regional intravenous (RI) delivery of rAAV to nonhuman primate skeletal muscle. Mol Ther 2010;18:151-160.
18. Favre D, Provost N, Blouin V, et al. Immediate and long-term safety of recombinant adeno-associated virus injection into the nonhuman primate muscle. Mol Ther 2001;4:559-566.
19. Arruda VR, Schuettrumpf J, Herzog RW, et al. Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. Blood 2004;103:85-92.
20. Wang L, Cao O, Swalm B, et al. Major role of local immune responses in antibody formation to factor IX in AAV gene transfer. Gene Ther 2005;12:1453-1464.
21. Wang L, Calcedo R, Bell P, et al. Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors. Hum Gene Ther 2011; 22:1389-1401.
22. Toromanoff A, Cherel Y, Guilbaud M, et al. Safety and efficacy of regional intravenous (r.i.) versus intramuscular (i.m.) delivery of rAAV1 and rAAV8 to nonhuman primate skeletal muscle. Mol Ther 2008;16:1291-1299.
23. Haurigot V, Mingozzi F, Buchlis G, et al. Safety of AAV factor IX peripheral transvenular gene delivery to muscle in hemophilia B dogs. Mol Ther 2010;18:1318-1329.
24. Ponnazhagan S, Mahendra G, Curiel DT, et al. Adenoassociated virus type 2-mediated transduction of human monocyte-derived dendritic cells: implications for ex vivo immunotherapy. J Virol 2001;75:9493-9501.
25. Liu Y, Chiriva-Internati M, You C, et al. Use and specificity of breast cancer antigen/milk protein BA46 for generating anti-self-cytotoxic T lymphocytes by recombinant adeno-associated virus-based gene loading of dendritic cells. Cancer Gene Ther 2005;12:304-312.
26. Aldrich WA, Ren C, White AF, et al. Enhanced transduction of mouse bone marrow-derived dendritic cells by repetitive infection with self-complementary adeno-associated virus 6 combined with immunostimulatory ligands. Gene Ther 2006;13:29-39.
27. Xin KQ, Mizukami H, Urabe M, et al. Induction of robust immune responses against human immunodeficiency virus is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells. J Virol 2006;80:11899-11910.
28. Veron P, Allo V, Riviere C, et al. Major subsets of human dendritic cells are efficiently transduced by self-complementary adeno-associated virus vectors 1 and 2. J Virol 2007;81: 5385-5394.
29. Ohshima S, Shin JH, Yuasa K, et al. Transduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle. Mol Ther 2009;17:73-80.
30. Wu T, Topfer K, Lin SW, et al. Self-complementary AAVs induce more potent transgene product-specific immune responses compared to a single-stranded genome. Mol Ther 2012;20:572-579.
31. Jooss K, Yang Y, Fisher KJ, et al. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol 1998;72:4212-4223.
32. Zhang Y, Chirmule N, Gao G, et al. CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors in vivo: role of immature dendritic cells. J Virol 2000;74:8003-8010.
33. Xu D, and Walker CM. Continuous CD8(+) T-cell priming by dendritic cell cross-presentation of persistent antigen following adeno-associated virus-mediated gene delivery. J Virol 2011;85:12083-12086.
34. Boisgerault F, Gross DA, Ferrand M, et al. Prolonged gene expression in muscle is achieved without active immune tolerance using MicrorRNA 142.3p-regulated rAAV gene transfer. Hum Gene Ther 2013;24:393-405.
35. Majowicz A, Maczuga P, Kwikkers KL, et al. Mir-142-3p target sequences reduce transgene-directed immunogenicity following intramuscular adeno-associated virus 1 vector-mediated gene delivery. J Gene Med 2013;15: 219-232.
36. Lu Y, and Song S. Distinct immune responses to transgene products from rAAV1 and rAAV8 vectors. Proc Natl Acad Sci U S A 2009;106:17158-17162.
37. Mays LE, Wang L, Lin J, et al. AAV8 induces tolerance in murine muscle as a result of poor APC transduction, T cell exhaustion and minimal MHCI upregulation on target cells. Mol Ther 2013;22:28-41.
38. Wang Z, Zhu T, Qiao C, et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol 2005;23:321-328.
39. Gowans JL. The recirculation of lymphocytes from blood to lymph in the rat. J Physiol 1959;146:54-69.
40. Mandl JN, Liou R, Klauschen F, et al. Quantification of lymph node transit times reveals differences in antigen surveillance strategies of naive CD4 + and CD8 + T cells. Proc Natl Acad Sci U S A 2012;109:18036-18041.
41. Masopust D, and Schenkel JM. The integration of T cell migration, differentiation and function. Nat Rev Immunol 2013;13:309-320.
42. Westermann J, Persin S, Matyas J, et al. IFN-gamma influences the migration of thoracic duct B and T lymphocyte subsets in vivo. Random increase in disappearance from the blood and differential decrease in reappearance in the lymph. J Immunol 1993;150:3843-3852.
43. Blaschke V, Micheel B, Pabst R, et al. Lymphocyte traffic through lymph nodes and Peyer's patches of the rat: B- and T-cell-specific migration patterns within the tissue, and their dependence on splenic tissue. Cell Tissue Res 1995;282: 377-386.
44. Case SS, Price MA, Jordan CT, et al. Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors. Proc Natl Acad Sci U S A 1999;96:2988-2993.
45. Miyoshi H, Smith KA, Mosier DE, et al. Transduction of human CD34 + cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science 1999;283:682-686.
46. An DS, Wersto RP, Agricola BA, et al. Marking and gene expression by a lentivirus vector in transplanted human and nonhuman primate CD34(+) cells. J Virol 2000;74:1286-1295.
47. Salmon P, Kindler V, Ducrey O, et al. High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors. Blood 2000;96:3392-3398.
48. Zaiss AK, Cotter MJ, White LR, et al. Complement is an essential component of the immune response to adenoassociated virus vectors. J Virol 2008;82:2727-2740.
49. Zaiss AK, and Muruve DA. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge. Gene Ther 2008;15:808-816.
50. Chen H, Lilley CE, Yu Q, et al. APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr Biol 2006;16:480-485.
51. McCarty DM, Monahan PE, and Samulski RJ. Selfcomplementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther 2001;8:1248-1254.
52. Cunningham EC, Sharland AF, Bishop GA. Liver transplant tolerance and its application to the clinic: can we exploit the high dose effect? Clin Dev Immunol 2013;2013: 419692.
53. Mount JD, Herzog RW, Tillson DM, et al. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood 2002; 99:2670-2676.
54. Dobrzynski E, Fitzgerald JC, Cao O, et al. Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells. Proc Natl Acad Sci U S A 2006;103:4592-4597.
55. Asokan A, Johnson JS, Li C, et al. Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther 2008;15:1618-1622.
56. Davidoff AM, Gray JT, Ng CY, et al. Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Mol Ther 2005;11:875-888.
57. Nakai H, Wu X, Fuess S, et al. Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver. J Virol 2005;79:3606-3614.
58. Graham T, McIntosh J, Work LM, et al. Performance of AAV8 vectors expressing human factor IX from a hepaticselective promoter following intravenous injection into rats. Genet Vaccines Ther 2008;6:9.
59. Anguela XM, Tafuro S, Roca C, et al. Nonviral-mediated hepatic expression of IGF-I increases Treg levels and suppresses autoimmune diabetes in mice. Diabetes 2013; 62:551-560.
60. Annoni A, Brown BD, Cantore A, et al. In vivo delivery of a microRNA-regulated transgene induces antigen-specific regulatory T cells and promotes immunologic tolerance. Blood 2009;114:5152-5161.
61. Sharland A, Logan GJ, Bishop A, et al. Liver-directed gene expression using recombinant AAV 2/8 vectors-a tolerogenic strategy for gene delivery? Discov Med 2010;9:519-527.
62. Sarukhan A, Camugli S, Gjata B, et al. Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors. J Virol 2001;75:269-277.
63. Porgador A, Snyder D, and Gilboa E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 1996;156:2918-2926.